These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 24549681)

  • 41. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.
    Baron R; Mayoral V; Leijon G; Binder A; Steigerwald I; Serpell M
    Curr Med Res Opin; 2009 Jul; 25(7):1663-76. PubMed ID: 19485723
    [TBL] [Abstract][Full Text] [Related]  

  • 43. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.
    Backonja M; Wallace MS; Blonsky ER; Cutler BJ; Malan P; Rauck R; Tobias J;
    Lancet Neurol; 2008 Dec; 7(12):1106-12. PubMed ID: 18977178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
    Morgan CC; Stephen Coad D
    Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adaptive designs for dose-finding studies based on sigmoid Emax model.
    Dragalin V; Hsuan F; Padmanabhan SK
    J Biopharm Stat; 2007; 17(6):1051-70. PubMed ID: 18027216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Extension of adaptive alpha allocation methods for strong control of the family-wise error rate.
    Li H; Sankoh AJ; D'Agostino RB
    Stat Med; 2013 Jan; 32(2):181-95. PubMed ID: 22806685
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pregabalin (Lyrica) and neuropathic pain syndromes].
    Jacquy J; Lossignol D; Sternon J
    Rev Med Brux; 2006; 27(5):445-50. PubMed ID: 17144644
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Optimal dose-finding designs with correlated continuous and discrete responses.
    Fedorov V; Wu Y; Zhang R
    Stat Med; 2012 Feb; 31(3):217-34. PubMed ID: 22162014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preserving the allocation ratio at every allocation with biased coin randomization and minimization in studies with unequal allocation.
    Kuznetsova OM; Tymofyeyev Y
    Stat Med; 2012 Apr; 31(8):701-23. PubMed ID: 22161821
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
    O'Connor AB; Noyes K; Holloway RG
    J Am Geriatr Soc; 2007 Aug; 55(8):1176-84. PubMed ID: 17661955
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Determining a minimum clinically important difference between treatments for a patient-reported outcome.
    Kirby S; Chuang-Stein C; Morris M
    J Biopharm Stat; 2010 Sep; 20(5):1043-54. PubMed ID: 20721790
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of stratification and adaptive methods for treatment allocation in an acute stroke clinical trial.
    Weir CJ; Lees KR
    Stat Med; 2003 Mar; 22(5):705-26. PubMed ID: 12587101
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of pain quality in a clinical trial of gabapentin extended release for postherpetic neuralgia.
    Jensen MP; Chiang YK; Wu J
    Clin J Pain; 2009 May; 25(4):286-92. PubMed ID: 19590476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Covariate-adjusted response-adaptive designs for binary response.
    Rosenberger WF; Vidyashankar AN; Agarwal DK
    J Biopharm Stat; 2001 Nov; 11(4):227-36. PubMed ID: 12018777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An urn model for odds-ratio-based response-adaptive phase III clinical trials for two or more treatments.
    Basak GK; Biswas A; Volkov S
    J Biopharm Stat; 2009 Sep; 19(5):838-56. PubMed ID: 20183447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Long-term efficacy and safety of pregabalin in patients with postherpetic neuralgia: results of a 52-week, open-label, flexible-dose study].
    Ogawa S; Suzuki M; Arakawa A; Yoshiyama T; Suzuki M
    Masui; 2010 Aug; 59(8):961-70. PubMed ID: 20715519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Missing data mechanisms in a dose-finding adaptive trial.
    Liu K; Entsuah R
    J Biopharm Stat; 2012; 22(2):329-37. PubMed ID: 22251177
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Generalized multidimensional dynamic allocation method.
    Lebowitsch J; Ge Y; Young B; Hu F
    Stat Med; 2012 Dec; 31(28):3537-44. PubMed ID: 22736449
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of the triangular test with response-adaptive treatment allocation.
    Coad DS; Ivanova A
    Stat Med; 2005 May; 24(10):1483-93. PubMed ID: 15706635
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response-adaptive treatment randomization for multiple comparisons of treatments with recurrent event responses.
    Gao J; Hu F; Cheung SH; Su PF
    Stat Methods Med Res; 2022 Aug; 31(8):1549-1565. PubMed ID: 35484830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.